EICHORCondition: Acute Myocardial Infarction · Sponsor: Viatris Innovation GmbH
The goal of this study is to find out how fast a drug called selatogrel (ACT-246475) can prevent platelets from binding together. This study will also help to find out more about the safety of this new drug. The drug selatogrel (ACT-246475) will be used in 2 different doses (8 mg or 16 mg) and will be administered in the thigh.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| OLV Ziekenhuis Aalst | Aalst, Belgium | — |
| UZLeuven | Leuven, Belgium | — |
| Galilee Medical Center | Nahariya, Israel | — |
| Universitätsspital Basel | Basel, Switzerland | — |
| University Hospital Bern | Bern, Switzerland | — |
| Cardiocentro Ticino | Lugano, Switzerland | — |
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03487445